NTRK1 and cancer: This characterizes TrkAIII as an oncogenic splice variant equivalent to TrkA fusion oncogenes [12,13], the potential importance of which is bolstered by reports that alternative splicing is a hallmark of cancer and represents an important alternative oncogene and oncogenic pathway activation mechanism in tumors that exhibit low mutation rates, which include NBs [14,15,16,17].